Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone

Molecular Cancer Research

Volumn 7, Issue 9, 2009, Pages 1543-1552

  Chhipa, Rishi Raj ^a   Lee, Kwang Soon ^a   Onate, Sergio ^b   Wu, Yue ^a   Ip, Clement ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; PEROXIREDOXIN 1;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG TARGETING; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; KNOCKOUT GENE; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; WILD TYPE;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN D1; DIHYDROTESTOSTERONE; DIMERIZATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; PEROXIREDOXINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TISSUE KALLIKREINS;

EID: 70349479241     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0546     Document Type: Article

References (44)

1. Brinkmann AO, Trapman J. Genetic analysis of androgen receptors in development and disease. Adv Pharmacol 2000;47:317-341
2. Santen RJ. Clinical review 37: endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992;75:685-689
3. Di Lorenzo G, De Placido S. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Int J Immunopathol Pharmacol 2006; 19:11-34.
4. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20:207-223 (Pubitemid 34595269)
5. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen- refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-1697 (Pubitemid 33130257)
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
7. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-1671
8. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998; 95:10820-10825 (Pubitemid 28413152)
9. Park SY, Kim YJ, Gao AC, et al. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006;66:5121-5129 (Pubitemid 43844934)
10. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, Park YM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res 2007;67:9294-9303 (Pubitemid 47535918)
11. Fujii J, Ikeda Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 2002;7:123-130 (Pubitemid 34700435)
12. Yanagawa T, Ishikawa T, Ishii T, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 1999;145:127-132 (Pubitemid 29459080)
13. Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 2000;156:27-35. (Pubitemid 30326764)
14. Kim JH, Bogner PN, Baek SH, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res 2008;14:2326-2333
15. Chen MF, Keng PC, Shau H, et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 2006;64:581-591 (Pubitemid 43083448)
16. Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y, Park YM. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res 2007;67:546-554 (Pubitemid 46192191)
17. Doesburg P, Kuil CW, Berrevoets CA, et al. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 1997;36:1052-1064 (Pubitemid 27076365)
18. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818
19. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-540
20. Ikonen T, Palvimo JJ, Janne OA. Interaction between the amino-and carboxyl- terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 1997;272:29821-29828 (Pubitemid 27508079)
21. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH([2])-terminal domain. J Biol Chem 1999; 274:37219-37225 (Pubitemid 30016799) (Pubitemid 129513905)
22. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z. A promoting role of androgen receptor in androgen-sensitive and-insensitive prostate cancer cells. Nucleic Acids Res 2007;35:2767-2776 (Pubitemid 47073687)
23. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1:Modifications to the androgen receptor. BJU Int 2005;95:1320-1326
24. Zoubeidi A, Zardan A, Beraldi E, et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007;67:10455-10465 (Pubitemid 350070821)
25. Shatkina L, Mink S, Rogatsch H, et al. The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol Cell Biol 2003;23:7189-7197 (Pubitemid 37211001)
26. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM. Specificity of ligand-dependent androgen receptor stabilization:receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 1995;9:208-218
27. Brooke GN, Parker MG, Bevan CL. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 2008;27:2941-2950
28. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002;62: 1496-1502 (Pubitemid 34407813)
29. Jung H, Kim T, Chae HZ, Kim KT, Ha H. Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J Biol Chem 2001;276:15504-15510 (Pubitemid 37373446) (Pubitemid 33648084)
30. Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem 2002;277:43175-43184
31. Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 1997;11:2456-2467
32. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-448 (Pubitemid 38173980)
33. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-6415
34. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-4454
35. Onate SA, Boonyaratanakornkit V, Spencer TE, et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 1998;273:12101-12108 (Pubitemid 28240570)
36. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999;19:8383-8392 (Pubitemid 30414032)
37. Agoulnik IU, Vaid A, Bingman WE III, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65: 7959-7967 (Pubitemid 41297275)
38. Chhipa RR, Kumari R, Upadhyay AK, Bhat MK. Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation. Exp Cell Res 2007;313: 3945-3958 (Pubitemid 350010931)
39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔ C(T)) Method. Methods 2001;25: 402-408 (Pubitemid 34164012)
40. Dong Y, Zhang H, Gao AC, Marshall JR, Ip C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther 2005;4:1047-1055 (Pubitemid 41079098)
41. Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A 1996;93:5517-5521 (Pubitemid 26159482) (Pubitemid 126585545)
42. Kim YJ, Lee WS, Ip C, Chae HZ, Park EM, Park YM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res 2006;66:7136-7142 (Pubitemid 44197691)
43. Umar A, Berrevoets CA, Van NM, et al. Functional analysis of a novel androgen receptor mutation, Q902K, in an individual with partial androgen insensitivity. J Clin Endocrinol Metab 2005;90:507-515 (Pubitemid 40116701)
44. Dubbink HJ, Hersmus R, Verma CS, et al. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol Endocrinol 2004; 18:2132-2150 (Pubitemid 39215246)